StockData

BioNTech vs Exelixis

BNTX and EXEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNTX and EXEL compare

Exelixis grew revenue faster over the last twelve months (9.1% versus 4.3% for BioNTech).

Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with −39.6% at BioNTech.

Exelixis scores higher on the StockData Score (18 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNTXEXEL
Size and price
Market cap–$16.7B
Share price$84.86$68.50
Change, 1 year−17.7%64.5%
Change, 5 years−75.6%302%
Beta (5Y)1.150.32
Employees5001,077
StockData Score
Total score318 (better)
Valuation score03 (better)
Growth score13 (better)
Performance score16 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–20.5×
P/S–6.7×
P/B–9.1×
EV/EBITDA–15.3×
P/FCF–14.4×
PEG–0.29
FCF yield–6.9%
Fair value–$66.21
Margin of safety–−3.5%
Growth
Revenue growth (TTM)4.3%9.1% (better)
Revenue growth, 5Y average42.9% (better)18.6%
Net income growth (TTM)–30.6%
EPS growth (TTM)–40.9%
EPS growth, 5Y average–51.4%
Profitability
Gross margin77.6%96.3% (better)
Operating margin−49.0%40.2% (better)
Net margin−39.6%35.5% (better)
FCF margin9.8%46.5% (better)
Return on equity–44.3%
Return on invested capital–75.0%
Financial health
Debt / equity–0.00
Interest coverage−20.1×–
Current ratio7.54 (better)3.21
Altman Z-score–17.36
Piotroski F-score57 (better)
Dividends and buybacks
Buyback yield–7.5%
Shareholder yield–7.5%
Ownership
Held by institutions18.9%106%
Held by insiders58.2%9.0%
Insider net buying, 12 months−$89.8M−$31.8M (better)
Short interest, % of float–11.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.